

TACT2 - effectiveness of chelation therapy in diabetes post MI

Location for study

BCDiabetes 400 - 210 West Broadway, Vancouver, V5Y 3W2

Study coordinator Dr. Ali Moshiri amoshiri@bcdiabetes.ca phone 604-683-3734 ext 7013

Eligibility:

Diabetes (Type 1 or Type 2)

Age 50+

Previous myocardial infarction/heart attack (Q waves, CK/troponin, wall motion abn or scar)

Serum creatinine < 176

Reasonable veins for repeated intravenous infusions

Non-smoker for 3+ months

Design & Sponsor:

multi-centre RCT, funded by the US National Institutes of Health (NIH)

Hypothesis:

Heavy metal (principally lead) pollutants are a major cardiovascular risk factor - removing lead from the blood will reduce all-cause mortality.

Intervention:

calcium disodium edetate 3 g (or placebo) IV infusion over 3 hours weekly for 40 weeks + multivitamins (or placebo)

Odds of getting each placebo: 50%

Patient reimbursement: \$50 cash per visit (\$2000 total)

Documents, studies & websites of interest

[TACT2 protocol](#)

[TACT 2 informed consent form](#)

["Chelation therapy - the science" 2019-Mar-28 UBC Cardiology Grand Rounds by Tom Elliott](#)

[CTV news clip on Barrie ONT site](#)

[TACT2 study website](#)

[TACT2 clinicaltrials.org listing](#)

[2013 JAMA overall benefits post MI \(of whom 38% have diabetes\)](#)

[2013 Circulation diabetes substudy: 41% reduct in MACE, 43% reduct all cause mortality](#)

[2018 Lancet epidemiology paper indicating lead as risk factor for cardiovascular death](#)

[2015 announcement of initial NIH funding for TACT2](#)

[background on PI Tony Lamas & history of final \\$37M NIH funding](#)

Short URL = <http://bit.ly/31KkBxz>